| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced a significant expansion of its drug delivery system manufacturing capacity, further strengthening its global footprint to meet the industry's evolving needs.
Stevanato Group team members at the Bad Oeynhausen site in northern Germany are pictured during the inauguration of the new cleanroom. At the center are Franco Stevanato, CEO; Marco Dal Lago, CFO; and Michele Monico, President of DDS and IVD Business Unit.
As part of its footprint optimization plan, the Company recently added a state-of-the-art production space for drug delivery devices to its facility in Bad Oeynhausen, northern Germany. This initiative provides more than 2,500 square meters of advanced manufacturing capacity designed to serve global pharma and biotech partners seeking robust and resilient European supply-chain integration.
The multi-million investment includes installation of an ISO 8 cleanroom environment, fully equipped for injection molding and automated assembly operations. These upgrades enable the site to support both Stevanato Group's proprietary device production and contract manufacturing services enhancing operational flexibility, scalability, and speed-to-market across the company's drug delivery systems portfolio.
The enhanced Bad Oeynhausen facility plays a pivotal role in advancing the production of key portfolio devices, including the Aidaptus® autoinjector and Alina® pen injector platforms. By integrating the Company's core capabilities in glass primary packaging, analytical services, and equipment manufacturing, Stevanato Group continues to reinforce its position as a trusted partner in enabling safe, effective, and patient-centric combination products tailored to individual customer requirements.
Posted In: STVN
